Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab.

ABSTRACT:

Purpose

Given the limited data on the effectiveness of atezolizumab plus bevacizumab (Ate/Bev) in patients with hepatocellular carcinoma with a Child-Pugh score (CPS) of 7, this study aims to evaluate the treatment's efficacy in this population and identify specific CPS 7 subgroups that may benefit from it.

Experimental design

This study included patients with advanced hepatocellular carcinoma who received Ate/Bev as first-line therapy between September 2020 and December 2023 at seven university hospitals. The primary outcome was overall survival (OS), whereas secondary outcomes included progression-free survival (PFS) and treatment response.

Results

Among the 374 included patients, those with CPS 5 (n = 169) demonstrated the highest OS and PFS, followed by patients w

SUBMITTER: Lee J 

PROVIDER: S-EPMC12521912 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature